NCT06321081 2024-03-20
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Beijing Hospital
Phase 2 Recruiting
Clinical Trials
17 trialsNCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05799443 2023-04-05
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05750290 2023-03-01
CKD-702 Plus Irinotecan in Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05595889 2022-11-29
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT01003964 2022-04-12
Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV
National Cancer Center, Korea
Phase 2 Completed
NCT03963193 2019-05-24
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
Henan Cancer Hospital
Phase 2 Unknown
NCT03222089 2018-03-27
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Fujian Cancer Hospital
Phase 2 Withdrawn
NCT03030937 2017-01-25
Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
Fujian Cancer Hospital
Phase 2 Unknown
NCT01380275 2014-09-25
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
National Cancer Center, Korea
Phase 2 Unknown
NCT00452634 2013-06-19
Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)
National Cancer Center, Korea
Phase 2 Completed
NCT00557102 2012-12-11
ERBIFORT
National Cancer Institute, France
Phase 2 Completed
NCT00620269 2011-11-07
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III
National Cancer Center, Korea
Phase 2 Unknown
NCT00512681 2009-09-18
TIROX2
National Cancer Center, Korea
Phase 2 Completed
NCT00506168 2007-07-25
Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer
National Cancer Center, Korea
Phase 2 Terminated
NCT00506571 2007-07-25
TIROX2
National Cancer Center, Korea
Phase 2 Unknown
NCT00506844 2007-07-25
ERBIRIX
National Cancer Center, Korea
Phase 2 Unknown